Loading...
XNYS
DNA
Market cap505mUSD
Dec 05, Last price  
9.25USD
1D
0.43%
1Q
-17.04%
IPO
-98.10%
Name

Ginkgo Bioworks Holdings Inc

Chart & Performance

D1W1MN
XNYS:DNA chart
P/E
P/S
2.23
EPS
Div Yield, %
Shrs. gr., 5y
-48.87%
Rev. gr., 5y
33.18%
Revenues
227m
-9.71%
98,285,00054,184,00076,657,000313,837,000477,706,000251,455,000227,043,000
Net income
-547m
L-38.73%
0-119,327,000-126,609,000-1,830,047,000-2,104,929,000-892,869,000-547,029,000
CFO
-320m
L+8.15%
-145,917,000-44,663,000-135,830,000-253,818,000-252,198,000-295,500,000-319,585,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
IPO date
Apr 19, 2021
Employees
1,292
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT